February 1, 2017
11am EST to 12pm EST

Sponsored by

Webinar Description:

Champions Oncology has established an advanced PDX platform for modeling hematology oncology malignancies including AML and ALL. The resource consists of leukapheresis AML and ALL clinical patient samples that are characterized for the ability to engraft into P1 study mice. Additionally, a resource for modeling defined patient populations as they progress co-clinically has been created by collecting blasts from patients as they progress in clinic. Both approaches are advantageous with the leukapheresis resource allowing for modeling large numbers of study mice across an established panel of patient samples and the co-clinical resource providing for modeling defined patient cohorts co-clinically.

Learning Objectives:

• Introduction to hematology AML and ALL modeling in P1 mice
• Describe the AML and ALL leukapheresis PDX modeling resource
• Describe the AML co-clinical PDX modeling resource

Speaker:

Neal Goodwin, Ph.D.

Vice President Corporate Research & Development

Champions Oncology

Neal Goodwin, PhD serves as Vice President Corporate Research Development for Champions Oncology (NASDAQ: CSBR). His responsibilities include development of a patient derived tumorgraft pharmacology portfolio for personalized oncology and translational oncology solutions. He previously served as the Director, Research and Development and the founding Program Director of JAX Cancer Services where he established a patient derived tumor biology program in collaboration with over 20 clinical cancer centers. Dr. Goodwin is a co-founder and a former Chief Scientific Officer of ProNAi Therapeutics (NASDAQ: DNAI) and he has served as a senior research scientist in genomic technologies at Pharmacia. Dr. Goodwin received a Ph.D. in Microbiology from The University of Montana and served a postdoctoral fellowship in functional genomics at The Jackson Laboratory with John Schimenti (now at Cornell).